Citation tools
"Macitentan reduces the risk of morbidity and mortality irrespective of the presence or absence of right ventricular (RV) impairment: Results from the randomised SERAPHIN trial in pulmonary arterial hypertension (PAH)." European Respiratory Journal
44.Suppl 58
(2014):
3419.
Web. 23 April. 2024.